Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.58 |
| ▸ | GLP1R | P43220 | 2/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | GIPR | P48546 | 7/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096606 | 0.86 | GCGR (0.45) | GCGRGLP1RTMEM97SIGMAR1EPHX2 | |
| SCHEMBL2650667 | 0.85 | LSS (0.58) | GCGRGLP1RTMEM97SIGMAR1EPHX2 | |
| SCHEMBL2663205 | 0.84 | GCGR (0.57) | GCGRGLP1REPHX2TPSAB1 | |
| SCHEMBL4095979 | 0.80 | HDAC1 (0.53) | GCGRGLP1R | |
| SCHEMBL2655178 | 0.78 | GCGR (0.56) | GCGRGLP1RTMEM97SIGMAR1EPHX2 | |
| SCHEMBL2663009 | 0.78 | GCGR (0.79) | GCGRGLP1RTMEM97SIGMAR1EPHX2 | |
| SCHEMBL6485438 | 0.76 | NR1D1 (0.36) | GCGRGLP1RTMEM97SIGMAR1 | |
| SCHEMBL4092836 | 0.76 | GCGR (0.62) | GCGRGLP1RGIPR | |
| SCHEMBL2662956 | 0.75 | GCGR (0.61) | GCGRGLP1REPHX2 | |
| SCHEMBL5926408 | 0.75 | EPHX2 (0.63) | GCGREPHX2GIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | GCGR 4654/4885GLP1R 4495/4885TMEM97 3638/4885 |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GLP1R 1/4885TMEM97 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.